# Brilinta Taiwan Post Approval Safety Study

Study · id `cardio:ct-nct02406248` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02406248](<https://clinicaltrials.gov/study/NCT02406248>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02406248

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

## Technical summary

Registry record NCT02406248. Allocation not applicable; no masking; primary purpose treatment. Start 2015-04-23 (actual); primary completion 2017-02-09 (actual). Results posted on 2018-10-15.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 108 participants (enrolled count; ClinicalTrials.gov record NCT02406248, source copy `cardio:ctgov-nct02406248-2018-10-15`, retrieved 2026-10-26)
- Started: 2015-04-23 (actual) (ClinicalTrials.gov record NCT02406248, source copy `cardio:ctgov-nct02406248-2018-10-15`, retrieved 2026-10-26)
- Primary completion: 2017-02-09 (actual) (ClinicalTrials.gov record NCT02406248, source copy `cardio:ctgov-nct02406248-2018-10-15`, retrieved 2026-10-26)
- Completion: 2017-02-09 (actual) (ClinicalTrials.gov record NCT02406248, source copy `cardio:ctgov-nct02406248-2018-10-15`, retrieved 2026-10-26)
- Results first posted: 2018-10-15 (ClinicalTrials.gov record NCT02406248, source copy `cardio:ctgov-nct02406248-2018-10-15`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT02406248, source copy `cardio:ctgov-nct02406248-2018-10-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02406248-2018-10-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Brilinta Taiwan Post Approval Safety Study
- Condition: Non ST-elevation Myocardial Infarction
- Intervention (Drug): Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: a3a07fb1a4aa5d4b32aa730a9a6ed7194055c6a2466995ac0ac02c17ed8c6d0c
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
